CAR T-cell Therapy Articles | Page 2

Memory-Related Genes May Overcome Resistance to CAR T-Cell Therapy in CLL
Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.
FDA Approves Tisagenlecleucel for Large B-Cell Lymphoma
The FDA has approved tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
 
Expert Covers Burgeoning Role of CAR T-Cell Therapy in Myeloma
Maung Myo Htut, MD, discusses the use of CAR T-cell therapy in multiple myeloma and the potential infusion of immunotherapy into treatment.
FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy
An off-the-shelf, dual-targeted chimeric antigen receptor T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies. 
Novel Agents, CAR T Cells Reinvigorate ALL Landscape
Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia. 
Brentjens Highlights BCMA, Next Steps With CAR T-Cell Therapy
Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.
T-Cell Fuel Source, Chemotherapy Exposure Reduce Potential to Develop CAR-T Therapy
Both prior chemotherapy and a dependence on glycolysis appear to reduce the potential to develop T cells into chimeric antigen receptor T-cell therapy.
Perl Highlights Latest CAR T-Cell Therapy Advances
Alexander Perl, MD, discusses the implementation of CAR T-cell therapy in ALL and other advances with this unique treatment across the spectrum of hematologic malignancies.
How Durable Are CAR T-Cell Therapies?
The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene ciloleucel in 2017, this gave hope to oncologists and patients with some types of leukemia and lymphoma who have exhausted all other options.
A panel of experts discusses the current state of CAR T-cell therapies and sheds light on the future directions of this therapeutic approach.
Publication Bottom Border
Border Publication
x